FOXF2 deficiency promotes hepatocellular carcinoma metastasis by inducing mesenchymal-epithelial transition

Abstract

OBJECTIVE:

The transcription factor FOXF2 is reported to be down-regulated in HCC. Its deficiency is correlated with shorter disease-free survival and overall survival of HCC patients; however, the mechanism remains to be elucidated.

MATERIALS AND METHODS:

In this study, we performed qRT-PCR and western blotting to confirm the down-regulated FOXF2 in HCC tissue and cell lines. Then the HCC cell line Huh7 transduced with FOXF2 shRNA was adopted in a series of in vitro and in vivo assays to evaluate the cell phenotype change, migration, invasion, proliferation, colonization of circulating cell and the formation of metastatic nodules.

RESULTS:

We found that FOXF2 was down-regulated in HCC tissues and cell lines. FOXF2 deficiency in Huh7 cells increased E-cadherin and decreased Vimentin. The down-regulation of FOXF2 impeded HCC cell migration and invasion capacity, but promoted the proliferation of HCC cells and the growth of subcutaneous tumors in nude mice, which indicated a mesenchymal-to-epithelial phenotypic change in Huh7 cells. FOXF2 deficiency enhanced the colonization of circulating HCC cell, thus promoted the formation of metastatic nodules.

CONCLUSIONS:

FOXF2 deficiency induced mesenchymal-epithelial transition (MET) in Huh7 cell which might facilitate the colonization of circulating tumor cells and the formation of metastasis.

Keywords

Hepatocellular carcinoma (HCC)metastasis forkhead box F2 (FOXF2)mesenchymal-epithelial transition (MET)

1. Introduction

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide, and its incidence is increasing globally [1]. Despite the advances in the diagnostic methods, surgical equipment & techniques and multidisciplinary therapy, the prognosis of HCC patients remains poor, with a total 5-year survival rate of around 12% [2]. The metastasis and recurrence of HCC are obstacles in the way towards better outcomes [3], thus the study on the mechanisms of HCC metastasis and recurrence is in urgent demand.

The forkhead box transcription factor family is characterized by a highly conserved forkhead/winged helix DNA binding domain and functions in a variety of biological processes, like embryogenesis, tissue development, metabolism, differentiation, proliferation and apoptosis [4, 5]. The FOX family is also reported to have an important role in the progression of many cancer types and is correlated with their prognosis [6].

FOXF2 is a member of FOX superfamily and plays a part in tissue development, extracellular matrix metabolism and epithelial-mesenchymal interactions [7, 8]. Studies have revealed that decreased FOXF2 in some cancer types, such as breast cancer [9], esophageal squamous cell carcinoma [10], prostate cancer [11] and stage I non-small cell lung cancer (NSCLC) [12] , predicts poor prognosis of patients. Low FOXF2 level could predict shorter disease-free survival, shorter overall survival and a higher frequency of lymph node metastasis of certain cancer types. The mechanisms beneath the correlation between decreased FOXF2 and early-onset of metastasis and relapse of tumor have not been well understood. The agreement lies in the fact that FOXF2 deficiency promotes tumor cell proliferation and inhibits apoptosis; however, more researches are in need to reveal the possible mechanisms. Wang et al. found that FOXF2 deficiency in basal-like breast cancer activated epithelial-mesenchymal transition (EMT) through up-regulating TWIST1 [13]. The research by Shi et al. demonstrated that FOXF2 down-regulation is common in HCC, and its expression levels are closely correlated with early metastasis and relapse of HCC [14], however, the mechanism has not been described.

In this study, we detected the expression profile of FOXF2 in HCC and focused on the mechanism underlying the correlation between FOXF2 deficiency and metastasis of HCC. A series of in vitro and in vivo experiments were performed in the cells with shRNA-mediated FOXF2 knockdown to elucidate the function of FOXF2 deficiency on HCC metastasis. We found that FOXF2 deficiency induced MET in HCC cells which facilitated the proliferation, colonization of circulating tumor cells and the formation of metastasis.

2. Materials and methods

2.1 Cell culture and reagents

The human hepatic cell line LO2 and human HCC cell line PLC, Huh7 and HepG2 were obtained from Cell Bank of Shanghai Institute of Biological Sciences, Chinese Academy of Sciences. The human HCC cell line MHCC97H was purchased from Shanghai Baili Biotechnology Company. All the cells were maintained in DMEM medium (Gibco, Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS), and were cultured in 5% CO ${}_{2}$ under humidified condition.

Antibodies against E-cadherin, Vimentin and glyce-raldehyde-3-phosphate dehydrogenase (GAPDH) were purchased from Cell Signaling Technology (Beverly, MA). The antibody against FOXF2 was purchased from Santa Cruz.

2.2 Animal model

BALB/c-nu mice aged 4 week old were subjected to subcutaneous tumor model and circulating tumor cell colonization model. For subcutaneous tumor model, cells were subcutaneously injected in the flanks of BALB/c-nu mice and observed for tumor growth for a period of 4 weeks. For circulating tumor cell colonization model, cells were injected through the tail vein of nude mice and cultivated for 4 weeks. After euthanasia, the lungs were harvested and the metastatic nodules were counted.

All animal experiments were approved by the Ethics Committee of the First Affiliated Hospital of Chinese PLA General Hospital.

2.3 Human HCC tissue specimens

Twenty pairs of HCC tissue and peritumor samples from the Department of Hepatobiliary Surgery, the First Affiliated Hospital of Chinese PLA General Hospital, were included in our research. This study was conducted in accordance with the Declaration of Helsinki (1964) and was approved by the Ethics Committee of the First Affiliated Hospital of Chinese PLA General Hospital. Informed consents were obtained from all participants.

2.4 Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)

Total RNA was extracted by using TRIzol (Invitrogen) and was reverse transcripted to cDNA using Primescript RT master mix (TaKaRa, Japan) according to the manufacturer’s instructions. Quantification of target gene expression was performed on ABI PRISM 7300 Sequence Detector by SYBR Green PCR Kit (TaKaRa, Japan). GAPDH was set as an internal control. The primer sequences were: FOXF2 (forward) (5’–AATGCCACTCGCCCTACAC-3’), FOXF2 (reverse) (5’-CGTTCTGGTGCAAGTAGCTCT-3’); GAPDH (forward) (5’-TGTGGGCATCAATGGATTT GG-3’), GAPDH (reverse) (5’-ACACCATGTATTCC GGGTCAAT-3’).

Figure 1.

The expression of FOXF2 in HCC tumor tissues and cell lines. A. FOXF2 mRNA levels in HCC tumor and peritumor tissues were measured by qRT-PCR. B. FOXF2 protein levels in a normal hepatic cell line LO2 and HCC cell line PLC, Huh7, MHCC97H and HepG2 were measured by western blotting.

2.5 Western blotting

Protein of 10–20 $\mu$ g was transferred to PVDF membranes and incubated with first antibody overnight at 4 ${}^{\circ}$ C. After being washed with TBST, the membranes were incubated with HRP-conjugated second antibody for 2 h at room temperature. The protein signals were developed by ECL (Millipore, Switzerland) for visualization.

2.6 Lentiviral transduction of shRNA

Lentivirus carrying a short hairpin RNA (shRNA) targeting FOXF2 was synthesized by Shanghai Gene-chem Company Ltd (GeneChem, Shanghai, China). FOXF2 targeting sequence was GTCCTCAACTTCA ATGGGATT. A shRNA nontargeting human gene was used as control. The lentiviral transduction was conducted following the manufacturer’s instructions to generate Huh7 cells with stable FOXF2 knock-down.

2.7 Wound healing assay

Wound healing assay was conducted by using Wou-nd Healing culture inserts (Ibidi, Munich, Germany) following the manufacturer’s instructions. Wound closure rate was calculated to represent the cell migration ability.

2.8 Transwell assay

Cell invasion ability in vitro was assessed by using Matrigel-coated transwell inserts (BD Biosciences) following the manufacturer’s instructions. Cells invaded to the opposite side the membranes were coun-ted.

Figure 2.

FOXF2 deficiency increased E-cadherin and decreased Vimentin. A. Huh7 cells were transfected with lentivirus carrying FOXF2 shRNA, and the knock-down efficiency was verified by qRT-PCR. Fold changes were relative to the FOXF2 mRNA expression of the control cells. B. Western blotting was used to measure the knock-down of FOXF2 protein level in Huh7 cells by FOXF2 shRNA transfection. C. The mRNA levels of E-cadherin and Vimentin were detected by qRT-PCR. D. The protein levels of E-cadherin and Vimentin were detected by western blotting.

2.9 Cell proliferation

Cell proliferation ability was assessed by colony formation assay and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. For colony formation assay, 1 $\times$ 10 ${}^{3}$ Cells were seeded in 6-well plates and cultivated for 30 days. Thereafter, the cells were fixed with ice cold methanol and stained with crystal violet. For MTT assay, 2 $\times$ 10 ${}^{3}$ cells were seeded in 96-well plates and cultured for indicated time. Then the cells were incubated with 10 $\mu$ L MTT solution (5 mg/mL) at 37 ${}^{\circ}$ C for 4 h. After removing the medium, the crystal formazen was dissolved in 100 $\mu$ L dimethyl sulphoxide (DMSO). The absorbance was measured at 570 nm.

2.10 Hematoxylin-eosin (H&E) staining

Figure 3.

FOXF2 deficiency inhibited migration and invasion of Huh7 cells. A. The migration ability of indicated cells was assessed by wound healing assay. B. Quantification of the wound closure rate in indicated cells. C. The invasion ability of indicated cells was assessed by transwell assay. D. Quantification of numbers of invasive Huh7 cells transfected with control and FOXF2 shRNA. ( ${}^{*}P<$ 0.05, ${}^{**}P<$ 0.01)

The nude mouse lungs were fixed in 4% paraformal-dehyde and embedded in paraffin. The slices of 5- $\mu$ m were stained with H&E for histological examination.

2.11 Statistical analysis

The data were expressed as mean $\pm$ standard deviation (SD). Student’s t test and one-way ANOVA were used to compare differences between groups. $P<$ 0.05 was considered significantly different.

3. Results

3.1 FOXF2 was down-regulated in HCC tumor tissues and cell lines

To reveal the role of FOXF2 in HCC, we first detected the expression profile of FOXF2 in 20 pairs of HCC tissues and peritumor tissues by qRT-PCR. The results showed that FOXF2 was down-regulated in HCC tumor tissues (Fig. 1A). We also screened the FOXF2 expression in 4 different HCC cell lines and a normal hepatic cell line LO2, and observed a notable decrease of FOXF2 in HCC cells (Fig. 1B). It was noticed that HCC cells with a mesenchymal phenotype (Huh7 and MHCC97H) tended to have more FOXF2 than epithelial HCC cells (PLC and HepG2).

The results in HCC were consistent with the findings by Shi et al. that FOXF2 was down-regulated in HCC tissues and cell lines.

3.2 FOXF2 deficiency increased E-cadherin and decreased Vimentin.

To further explore the effect of FOXF2 deficiency on HCC progression. We used Huh7 cells for further experiments and transfected Huh7 cells with lentivirus carrying FOXF2 shRNA sequences. The knock-down efficiency was verified by qRT-PCR and western blotting, respectively. The qRT-PCR results showed that the interfering rate was around 70% (Fig. 2A). The western blotting results confirmed decreased FOXF2 in Huh7 cells transfected with FOXF2 shRNA (Fig. 2B).

The research by Shi et al. demonstrated that FOXF2 deficiency was correlated with shorter disease-free survival rate in HCC patients. The down-regulated FOXF2 was predictive of recurrence and metastasis of HCC. Because FOXF2 was involved in epithelial-mesenchymal interaction which was a significant me-chanism underlying tumor metastasis, our researches focused on the changes of cell phenotypes. We first detected the two regular cell phenotype markers E-cadherin and Vimentin in Huh7 cells with FOXF2 shRNA transfection. We found increased E-cadherin and decreased Vimentin mRNA levels after inhibiting FOXF2 (Fig. 2C). The protein changes were consistent with that in mRNA levels (Fig. 2D).

The above results indicated that the down-regulation of FOXF2 might induce a mesenchymal to epithelial phenotypic change in HCC cells

3.3 FOXF2 deficiency inhibited migration and invasion of Huh7 cells

Accompanied by the phenotypic changes, the migration and invasion capacity of tumor cells also changes. So in our further researches, we accessed the migration and invasion ability of Huh7 cells after inhibiting FOXF2. By wound healing assay, we found that FOXF2 deficiency impeded the migration of Huh7 cell (Fig. 3A). The decreased wound closure rate was significantly different (Fig. 3B). We also accessed the invasion capacity of Huh7 with FOXF2 deficiency by transwell assay. The results showed decreased invasion of Huh7 cells after inhibiting FOXF2 (Fig. 3C). The changes was also significantly different (Fig. 3D).

Based on the above results, we speculated that FOXF2 deficiency induced MET in HCC cells.

3.4 FOXF2 deficiency promoted Huh7 cell proliferation and the growth of subcutaneous tumor in nude mice

When tumor cells underwent MET, they usually acquired enhanced proliferation to form metastasis, so we further evaluated the proliferative capacity of Huh7 cells transfected with FOXF2 shRNA. We found increased colony formation of Huh7 cells with stable FOXF2 knock-down (Figs 4A and B). The cell growth curves demonstrated that FOXF2 knock-down significantly promoted the proliferation of Huh7 cells (Fig. 4C). To test whether FOXF2 deficiency could alter the proliferation of Huh7 cells in vivo, Huh7 cells with stable FOXF2 knock-down were injected subcutaneously in the flank of nude mice. Tumor volumes were measured 4 weeks after injection which showed increased volume in the group of Huh7 cells with FOXF2 knock-down (Fig. 4D).

Figure 4.

FOXF2 deficiency promoted Huh7 cell proliferation and the growth of subcutaneous tumor in nude mice. A. Colony formation assay was adopted to measure the proliferation of indicated cells. B. Quantification of colony numbers of indicated cells. C. Cell proliferation of indicated cells was determined by MTT assay. D. Huh7 cells transfected with control shRNA or FOXF2 shRNA were injected subcutaneously in nude mice. The tumor volumes were quantified 3 weeks after injection. ( ${}^{*}P<$ 0.05, ${}^{**}P<$ 0.01)

3.5 FOXF2 deficiency promoted the colonization of circulating Huh7 cells and the formation of metastatic nodules in nude mouse lung

The research by Ocana et al. demonstrated that MET process was necessary for circulating tumor cells to colonize and form metastasis [15]. Tumor cells that underwent EMT had to go through a reversed transversion to acquire an epithelial phenotype again to form metastatic nodules, so we tested whether FOXF2 deficiency affect the colonization of circulating HCC cells. Huh7 cells with stable FOXF2 knock-down and control cells were injected through the tail vein of nude mice. Four weeks after injection, the metastatic nodules in the lung were counted. We found that FOXF2 deficiency increased the formation of lung metastatic nodules (Fig. 5A), which was confirmed by H&E staining of the lung sections (Fig. 5B).

Figure 5.

FOXF2 deficiency promoted the colonization of circulating Huh7 cells and the formation of metastatic nodules in nude mouse lung. A. Quantification of metastatic lung nodules formed in nude mice injected with Huh7 cells with control shRNA or FOXF2 shRNA. B. Representative images of H&E staining of lung sections from nude mice injected with indicated cells.

4. Discussion

In our research, we found that FOXF2 was down-regulated in HCC tissues and cell lines, and this was consistent with existing studies [14]. Then we focused on the possible mechanisms underlying the correlation between FOXF2 deficiency and the early metastasis by a series of in vitro and in vivo assays. We found that the FOXF2 deficiency in HCC cells increased E-cadherin and reduced Vimentin, which indicated a mesenchymal to epithelial phenotypic change. The down-regulation of FOXF2 impeded HCC cell migration and invasion capacity, but promoted the proliferation of HCC cells and the growth of subcutaneous tumors in nude mice. FOXF2 deficiency enhanced the colonization of circulating HCC cell, thus promoted the formation of metastatic nodules.

The transcription factor FOXF2, a member of FOX superfamily, is involved in tissue development, ECM synthesis and epithelial-mesenchymal interactions.FOXF2 has been revealed as a tumor suppressor and the down-regulation of FOXF2 correlated with poor prognosis in divergent cancer types [9, 14]. The role of FOXF2 in regulating the epithelial-mesenchymal interaction, migration and invasion was controversial. In cancer metastasis, many researches showed that decreased FOXF2 promoted migration and invasion of tumor cell by inducing EMT [13, 16, 17, 18]. However, the recent research by Kundu et al. demonstrated that inhibited FOXF2 impeded cell invasion of lung cancer. FOXF2 was increased in mesenchymal-like metastatic lung cancer cells. The FOXF2 expression could induce EMT, migration, invasion in lung cancer cells [19]. The research by Lo et al. also showed that FOXF2 was required for cell migration and invasion of basal-like breast cancer cells by regulating the expression of genes implicated in EMT regulation [20]. Our research showed that decreased FOXF2 inhibited the mesenchymal features of HCC cell such as the expression of Vimentin and the migration and invasion capacity. This was consistent with the study by Kundu and Lo.

In our research, we also found that FOXF2 deficiency promoted cell proliferation of HCC cell. The enhanced cell viability might be the results of Wnt/ $\beta$ -catenin pathway activation. It was reported that FOXF2 inhibited Wnt5a, the activation of which could act through canonical and non-canonical Wnt pathways to promote cell proliferation and reduce apoptosis [21, 22]. The inhibition of FOXF2 in HCC cell might re-activate Wnt pathway, thus led to enhance cell proliferation.

So based on the results that FOXF2 deficiency inhibited cell invasiveness and promoted cell proliferation of HCC cells, we speculated that FOXF2 deficiency induced MET in HCC cells. MET was recognized as a revere process of EMT, in which mesenchymal tumor cells disseminating from the origin site acquired the epithelial phenotypes again to form metastatic neoplasm [23]. The EMT progression facilitated tumor cells with increased motility and invasiveness, promoted the dissemination from original tumor sites and infiltration into circulation [24]. However, those circulating tumor cells could not form metastasis without the happening of the reverse process MET. Tumor cells underwent MET to re-differentiate and to acquire enhanced proliferation during colonization and formation of metastasis [25]. So MET was necessary for efficient colonization and macrometastasis [15, 26].

Several studies have been conducted to elucidate how FOXF2 was down-regulated in tumor cells. The decreased FOXF2 level was often the results of some increased microRNAs. The research by Kundu et al. demonstrated that the miR-183/96/182 cluster could directly target FOXF2 to inhibit the migration and invasion of lung cancer cells [19]. In colorectal cancer, miR-182 could bind to the 3’ untranslated region (3’UTR) of FOXF2 mRNA to promote cell growth and invasion [18]. MiR-182-5p was also reported to be able to inhibit FOXF2 in prostate cancer [17]. MiR-301 was another miRNA targeting FOXF2 in breast cancer [27]. In HCC, miRNA-519a was found to be up-regulated. MiRNA-519a enhanced the proliferation and inhibited apoptosis of HCC cells by targeting FOXF2 [28]. The way how FOXF2 is down-regulated in HCC has not been extensively described yet. Besides miRNA-519a, other three miRNAs mentioned above are also promising ones that could target FOXF2 in HCC. MiR-183/96/182, miR-182 and miR-301 were reported to be up-regulated in HCC and correlate with poor prognosis of HCC. Those miRNAs have a vital role in modulating the cell growth and invasion of HCC cells [29, 30, 31]. Leung et al. found that miR-183/96/182 was over-expressed in HCC tissues and correlated with metastatic features including presence of microvascular invasion, advanced tumor differentiation, and shorter recurrence-free survival of HCC. What was more, the downstream target of miR-183/96/182 was FOXO1, another FOX family member [32]. We speculate that the down-regulated FOXF2 in HCC is also the consequence of some aberrantly expressed miRNAs, including miR-519a and miR-183/96/182.

In summary, we conclude that decreased FOXF2 is common in HCC tissues and cell lines. The FOXF2 deficiency in cells induces MET thus promotes the metastasis of HCC. However, the way how FOXF2 is down-regulated in HCC needs further investigations.

References

Torre

L.A.

Bray

Siegel

R.L.

Ferlay

Lortet-Tieulent

and Jemal

, Global cancer statistics, 2012, CA Cancer J Clin 65 (2015), 87–108.

El-Serag

H.B.

, Hepatocellular carcinoma, N Engl J Med 365 (2011), 1118–1127.

El-Serag

H.B.

and Rudolph

K.L.

, Hepatocellular carcinoma: epidemiology and molecular carcinogenesis, Gastroenterology 132 (2007), 2557–2576.

Katoh

and Katoh

, Human FOX gene family (Review), Int J Oncol 25 (2004), 1495–1500.

Carlsson

and Mahlapuu

, Forkhead transcription factors: key players in development and metabolism, Dev Biol 250 (2002), 1–23.

Myatt

S.S.

and Lam

E.W.

, The emerging roles of forkhead box (Fox) proteins in cancer, Nat Rev Cancer 7 (2007), 847–859.

Aitola

Carlsson

Mahlapuu

Enerback

and Pelto-Huikko

, Forkhead transcription factor FoxF2 is expressed in mesodermal tissues involved in epithelio-mesenchymal interactions, Dev Dyn 218 (2000), 136–149.

Westergren

Nilsson

Heglind

Arani

Grande

Cederberg

Ahren

and Enerback

, Overexpression of Foxf2 in adipose tissue is associated with lower levels of IRS1 and decreased glucose uptake in vivo, Am J Physiol Endocrinol Metab 298 (2010), E548–E554.

Kong

P.Z.

Yang

X.Q.

and Feng

Y.M.

, Decreased FOXF2 mRNA expression indicates early-onset metastasis and poor prognosis for breast cancer patients with histological grade II tumor, PLoS One 8 (2013), e61591.

10.

Zheng

Y.Z.

Wen

Cao

Yang

Luo

K.J.

Liu

Q.W.

Huang

Q.Y.

Chen

J.Y.

and Fu

J.H.

, Decreased mRNA expression of transcription factor forkhead box F2 is an indicator of poor prognosis in patients with resected esophageal squamous cell carcinoma, Mol Clin Oncol 3 (2015), 713–719.

11.

van der Heul-Nieuwenhuijsen Dits

Van Ijcken

, de Lange and Jenster

, The FOXF2 pathway in the human prostate stroma, Prostate 69 (2009), 1538–1547.

12.

Kong

P.Z.

G.M.

Tian

Song

and Shi

, Decreased expression of FOXF2 as new predictor of poor prognosis in stage I non-small cell lung cancer, Oncotarget (2016).

13.

Wang

Q.S.

Kong

P.Z.

X.Q.

Yang

and Feng

Y.M.

, FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer, Breast Cancer Res 17 (2015), 30.

14.

Shi

Liu

Huang

Shen

Zhang

Han

and Yang

, Loss of FOXF2 Expression Predicts Poor Prognosis in Hepatocellular Carcinoma Patients, Ann Surg Oncol 23 (2016), 211–217.

15.

Ocana

O.H.

Corcoles

Fabra

Moreno-Bueno

Acloque

Vega

Barrallo-Gimeno

Cano

and Nieto

M.A.

, Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1, Cancer Cell 22 (2012), 709–724.

16.

Cai

Tian

A.X.

Wang

Q.S.

Kong

P.Z.

X.Q.

and Feng

Y.M.

, FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer, Cancer Lett 367 (2015), 129–137.

17.

Hirata

Ueno

Shahryari

Deng

Tanaka

Tabatabai

Z.L.

Hinoda

and Dahiya

, MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer, PLoS One 8 (2013), e55502.

18.

Zhang

Zhao

Shi

Yao

Zhang

Guo

and Liu

, Overexpression of MACC1 and the association with hepatocyte growth factor/c-Met in epithelial ovarian cancer, Oncol Lett 9 (2015), 1989–1996.

19.

Kundu

S.T.

Byers

L.A.

Peng

D.H.

Roybal

J.D.

Diao

Wang

Tong

Creighton

C.J.

and Gibbons

D.L.

, The miR-200 family and the miR-183 ∼ 96 ∼ 182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers, Oncogene 35 (2016), 173–186.

20.

P.K.

Lee

J.S.

Liang

and Sukumar

, The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression, Cell Signal 28 (2016), 1502–1519.

21.

Ormestad

Astorga

Landgren

Wang

Johansson

B.R.

Miura

and Carlsson

, Foxf1 and Foxf2 control murine gut development by limiting mesenchymal Wnt signaling and promoting extracellular matrix production, Development 133 (2006), 833–843.

22.

Nik

A.M.

Reyahi

Ponten

and Carlsson

, Foxf2 in intestinal fibroblasts reduces numbers of Lgr5(+) stem cells and adenoma formation by inhibiting Wnt signaling, Gastroenterology 144 (2013), 1001–1011.

23.

Gunasinghe

N.P.

Wells

Thompson

E.W.

and Hugo

H.J.

, Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer, Cancer Metastasis Rev 31 (2012), 469–478.

24.

Polyak

and Weinberg

R.A.

, Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits, Nat Rev Cancer 9 (2009), 265–273.

25.

Bonnomet

Syne

Brysse

Feyereisen

Thompson

E.W.

Noel

Foidart

J.M.

Birembaut

Polette

and Gilles

, A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer, Oncogene 31 (2012), 3741–3753.

26.

Bardia

Wittner

B.S.

Stott

S.L.

Smas

M.E.

Ting

D.T.

Isakoff

S.J.

Ciciliano

J.C.

Wells

M.N.

Shah

A.M.

Concannon

K.F.

Donaldson

M.C.

Sequist

L.V.

Brachtel

Sgroi

Baselga

Ramaswamy

Toner

Haber

D.A.

and Maheswaran

, Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition, Science 339 (2013), 580–584.

27.

Shi

Gerster

Alajez

N.M.

Tsang

Waldron

Pintilie

Hui

A.B.

Sykes

P’ng

Miller

McCready

Fyles

and Liu

F.F.

, MicroRNA-301 mediates proliferation and invasion in human breast cancer, Cancer Res 71 (2011), 2926–2937.

28.

Shao

Cao

Liu

Mei

Zhang

and Xu

, MicroRNA-519a promotes proliferation and inhibits apoptosis of hepatocellular carcinoma cells by targeting FOXF2, FEBS Open Bio 5 (2015), 893–899.

29.

Z.B.

Z.Z.

Chu

H.T.

and Jia

, MiR-21 and miR-183 can simultaneously target SOCS6 and modulate growth and invasion of hepatocellular carcinoma (HCC) cells, Eur Rev Med Pharmacol Sci 19 (2015), 3208–3217.

30.

Zhang

Daucher

Armistead

Russell

and Kottilil

, MicroRNA expression profiling in HCV-infected human hepatoma cells identifies potential anti-viral targets induced by interferon-alpha, PLoS One 8 (2013), e55733.

31.

Chen

Chu

Cao

Shao

and Wang

, Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma, Tumour Biol 36 (2015), 7439–7447.

32.

Leung

W.K.

Chan

A.W.

Law

P.T.

and Wong

, Wnt/beta-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion, Cancer Lett 362 (2015), 97–105.